Alembic announces USFDA final approval for Travoprost Ophthalmic Solution USP, 0.004%
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5%/0.3%, of Bausch & Lomb
The product will be marketed by Dr. Reddy's Laboratories Inc.
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
Sumatriptan injection is indicated in adults for the acute treatment of migraine
Glenmark will begin distribution in November 2025
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Subscribe To Our Newsletter & Stay Updated